Pharmaceutical Investing AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena
Pharmaceutical Investing AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia
Pharmaceutical Investing AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration
Pharmaceutical Investing AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Feraheme
Pharmaceutical Investing AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
Pharmaceutical Investing AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™
AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs for Makena® and Feraheme®
